Evaluation of [O-methyl-11C]RS.15385-197 as a positron emission tomography radioligand for central α2-adrenoceptors

European Journal of Nuclear Medicine

Volumn 27, Issue 5, 2000, Pages 475-484

  Hume, Susan P ^a   Hirani, Ella ^a   Opacka Juffry, Jolanta ^a   Osman, Safiye ^a   Myers, Ralph ^a   Gunn, Roger N ^a   McCarron, Julie A ^a   Clark, Robin D ^b   Melichar, Jan ^c   Nutt, David J ^c   Pike, Victor W ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROCHE BIOSCIENCE   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Positron emission tomography; RS 15385 197; RS 79948 197; 2 adrenoceptor

Indexed keywords

12 ETHYLSULFONYL 5,8,8A,9,10,11,12,12A,13,13A DECAHYDRO 3 METHOXY 6H ISOQUINO[2,1 G][1,6]NAPHTHYRIDINE; 5,8,8A,9,10,11,12,12A,13,13A DECAHYDRO 3 METHOXY 12 (ETHYLSULFONYL) 6H ISOQUINOL[2,1 G][1,6]NAPHYRIDINE; ALPHA 2 ADRENERGIC RECEPTOR; CARBON 11; DELEQUAMINE; DELEQUAMINE C 11; DRUG METABOLITE; RADIOLIGAND; TRITIUM; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANIMAL TISSUE; ARTICLE; BRAIN SCINTISCANNING; CEREBELLUM; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG UPTAKE; HUMAN; MALE; NONHUMAN; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; RECEPTOR DENSITY;

BIOCHEMISTRY; BRAIN; CARBON; ELECTRONS; POSITRONS; PROTEINS; RADIOACTIVITY; RATS;

BIODISTRIBUTIONS; BRAIN UPTAKE; CARBON-11; IN-VIVO; LOCALISATION; NON-SPECIFIC BINDING; RADIOLIGANDS; RS-15385-197; RS-79948-197; Α2-ADRENOCEPTOR;

POSITRON EMISSION TOMOGRAPHY;

EID: 0034116218     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050531     Document Type: Article

References (28)

1. 2-adrenoceptors in the human brain. Brain Res 1992; 585: 116-127.
2. 2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem 1998; 70: 1114-1123.
3. 2-adrenergic receptor radioligand for PET studies. Nucl Med Biol 1998; 25: 127-133.
4. 11C]WY 26703. Use as a radioligand of positron emission tomography. Receptor 1992; 2: 241-252.
5. 5. Solin O, Enas JD, Bergman J, Haaparanta M, VanBrocklin HF, Budinger TF. Synthesis of [F-18]fluoroatipamezole. Biodistribution in rats. J Nucl Med 1996; 37: 51P.
6. 2-adrenoceptors. Nucl Med Biol 1992; 19: 841-849.
7. 2-adrenoceptors. Eur J Pharmacol 1996; 317: 67-73.
8. 8. Clark RD, Repke DB, Berger J, Nelson JT, Kilpatrick AT, Brown CM, MacKinnon AC, Clague RU, Spedding M. Structure-affinity relationships of the 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1,6]naphthyridines at α-adrenoceptors. J Med Chem 1991; 34: 705-717.
9. 2-adrenoceptors: implications for receptor classification. Br J Pharmacol 1992; 106: 1011-1018.
10. 10. Enas JD, Clark RD, VanBrocklin HF, Biegon A, Hanrahan SM, Budinger TF. Synthesis and biological evaluation of [F-18]RS-15385-FP: a potent and selective alpha-2 adrenergic receptor radioligand for PET. J Nucl Med 1996; 37: 40P.
11. 2-adrenoceptors in vivo. J Lab Compd Radiopharm 1997; 40: 642-644.
12. 14C]iodoantipyrine. Am J Physiol 1990; 258: H1585-H1598.
13. 13. Pardridge WM, Oldendorf WH. Kinetics of blood-brain barrier transport of hexoses. Biochem Biophys Acta 1975; 382: 377-392.
14. 14. Spinks TJ, Jones T, Bailey DL, Townsend DW, Grootoonk S, Bloomfield PM, Gilardi M-C, Casey ME, Sipe B, Reed J. Physical performance of a positron tomograph for brain imaging with retractable septa. Phys Med Biol 1992; 37: 1637-1655.
15. 15. Ranicar ASO, Williams CW, Schnorr L, Clark JC, Rhodes CG, Bloomfield PM, Jones T. The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO photomultiplier assembly and non-stick tubing. Med Prog Technol 1991; 17: 259-264.
16. 16. Grootoonk S, Spinks TJ, Sashin D, Spyrou NM, Jones T. Correction for scatter in 3D brain PET using a dual energy window method. Phys Med Biol 1996; 41: 2757-2774.
17. 17. Kinahan PE, Rogers JG. Analytical 3-D image reconstruction using all detected events. IEEE Trans Nucl Sci 1989; NS-36: 964-968.
18. 18. Robb RA, Hanson DP. A software system for interactive and quantitative visualization of multidimensional biomedical images. Aust Phys Eng Sci Med 1991; 14: 9-30.
19. 19. Studholme C, Hill DLG, Hawkes DJ. Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys 1997; 24: 25-35.
20. 11C]raclopride studies. J Cereb Blood Flow Metab 1996; 16: 42-52.
21. 21. Lammertsma AA, Brooks DJ, Beaney RP, Turton DR, Kensett MJ, Heather JD, Marshall J, Jones T. In vivo measurement of regional cerebral haematocrit using positron emission tomography. J Cereb Blood Flow Metab 1984; 4: 317-322.
22. 22. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6: 279-287.
23. 23. Hume SP, Brown DJ, Ashworth S, Hirani E, Luthra SK, Lammertsma AA. In vivo saturation kinetics of two dopamine transporter probes measured using a small animal positron emission tomography scanner. J Neurosci Methods 1997; 76: 45-51.
24. 2-adrenoceptors: pharmacological and molecular biologic evidence converge. Trends Pharmacol Sci 1988; 9: 356-361.
25. 2-adrenoceptor antagonist. Br J Pharmacol 1993; 108: 516-525.
26. 26. Greig NH. Drug delivery to the brain. In: Neuwelt J, Edward A, eds. Implications of the blood-brain barrier and its manipulation, vol 1. New York: Plenum; 1989: 311-357.
27. 27. Lin JH, Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997; 49: 403-450.
28. 28. Riant P, Urien S, Albengres E, Renouard A, Tillement JP. Effects of the binding of imipramine to erythrocytes and plasma proteins on its transport through the rat blood-brain barrier. J Neurochem 1988; 58: 421-425.